Proline-rich AKT substrate of 40-kDa (PRAS40) in the pathophysiology of cancer

Ritu Malla; Charles R. Ashby; Narayanan K. Narayanan; Bhagavathi Narayanan; Jesika S. Faridi; Amit K. Tiwari

doi:10.1016/j.bbrc.2015.05.041

Proline-rich AKT substrate of 40-kDa (PRAS40) in the pathophysiology of cancer

Ritu Malla
, Charles R. Ashby
, Narayanan K. Narayanan
, Bhagavathi Narayanan
, Jesika S. Faridi
, Amit K. Tiwari

University of the Pacific
St. John's University
New York University
University of Toledo

Research output: Contribution to journal › Short survey › peer-review

38 Scopus citations

Abstract

Dysregulation of PI3K-AKT-mTOR pathway has been reported in various pathologies, such as cancer and insulin resistance. The proline-rich AKT substrate of 40-kDa (PRAS40), also known as AKT substrate 1 (AKT1S1), lies at the crossroads of these cascades and inhibits the activity of the mTOR complex 1 (mTORC1) kinase. This review discusses the role of PRAS40 and possible feedback mechanisms, and alterations in AKT/PRAS40/mTOR signaling that have been implicated in the pathogenesis of tumor progression. Additionally, we probed new datasets extracted from Oncomine, a cancer microarray database containing datasets derived from patient samples, to further understand the role of PRAS40 (AKT1S1). These data strongly supports the hypothesis that PRAS40 may serve as a potential therapeutic target for various cancers.

Original language	English
Pages (from-to)	161-166
Number of pages	6
Journal	Biochemical and Biophysical Research Communications
Volume	463
Issue number	3
DOIs	https://doi.org/10.1016/j.bbrc.2015.05.041
State	Published - 14 Jun 2015
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Cancer therapeutics
PI3K/AKT
PRAS40
mTORC1

Access to Document

10.1016/j.bbrc.2015.05.041

Cite this

@article{f874753aa471495ba4c12aed7023c925,

title = "Proline-rich AKT substrate of 40-kDa (PRAS40) in the pathophysiology of cancer",

abstract = "Dysregulation of PI3K-AKT-mTOR pathway has been reported in various pathologies, such as cancer and insulin resistance. The proline-rich AKT substrate of 40-kDa (PRAS40), also known as AKT substrate 1 (AKT1S1), lies at the crossroads of these cascades and inhibits the activity of the mTOR complex 1 (mTORC1) kinase. This review discusses the role of PRAS40 and possible feedback mechanisms, and alterations in AKT/PRAS40/mTOR signaling that have been implicated in the pathogenesis of tumor progression. Additionally, we probed new datasets extracted from Oncomine, a cancer microarray database containing datasets derived from patient samples, to further understand the role of PRAS40 (AKT1S1). These data strongly supports the hypothesis that PRAS40 may serve as a potential therapeutic target for various cancers.",

keywords = "Cancer therapeutics, PI3K/AKT, PRAS40, mTORC1",

author = "Ritu Malla and Ashby, \{Charles R.\} and Narayanan, \{Narayanan K.\} and Bhagavathi Narayanan and Faridi, \{Jesika S.\} and Tiwari, \{Amit K.\}",

year = "2015",

month = jun,

day = "14",

doi = "10.1016/j.bbrc.2015.05.041",

language = "English",

volume = "463",

pages = "161--166",

journal = "Biochemical and Biophysical Research Communications",

issn = "0006-291X",

publisher = "Elsevier B.V.",

number = "3",

}

TY - JOUR

T1 - Proline-rich AKT substrate of 40-kDa (PRAS40) in the pathophysiology of cancer

AU - Malla, Ritu

AU - Ashby, Charles R.

AU - Narayanan, Narayanan K.

AU - Narayanan, Bhagavathi

AU - Faridi, Jesika S.

AU - Tiwari, Amit K.

PY - 2015/6/14

Y1 - 2015/6/14

N2 - Dysregulation of PI3K-AKT-mTOR pathway has been reported in various pathologies, such as cancer and insulin resistance. The proline-rich AKT substrate of 40-kDa (PRAS40), also known as AKT substrate 1 (AKT1S1), lies at the crossroads of these cascades and inhibits the activity of the mTOR complex 1 (mTORC1) kinase. This review discusses the role of PRAS40 and possible feedback mechanisms, and alterations in AKT/PRAS40/mTOR signaling that have been implicated in the pathogenesis of tumor progression. Additionally, we probed new datasets extracted from Oncomine, a cancer microarray database containing datasets derived from patient samples, to further understand the role of PRAS40 (AKT1S1). These data strongly supports the hypothesis that PRAS40 may serve as a potential therapeutic target for various cancers.

AB - Dysregulation of PI3K-AKT-mTOR pathway has been reported in various pathologies, such as cancer and insulin resistance. The proline-rich AKT substrate of 40-kDa (PRAS40), also known as AKT substrate 1 (AKT1S1), lies at the crossroads of these cascades and inhibits the activity of the mTOR complex 1 (mTORC1) kinase. This review discusses the role of PRAS40 and possible feedback mechanisms, and alterations in AKT/PRAS40/mTOR signaling that have been implicated in the pathogenesis of tumor progression. Additionally, we probed new datasets extracted from Oncomine, a cancer microarray database containing datasets derived from patient samples, to further understand the role of PRAS40 (AKT1S1). These data strongly supports the hypothesis that PRAS40 may serve as a potential therapeutic target for various cancers.

KW - Cancer therapeutics

KW - PI3K/AKT

KW - PRAS40

KW - mTORC1

UR - https://www.scopus.com/pages/publications/84930924235

U2 - 10.1016/j.bbrc.2015.05.041

DO - 10.1016/j.bbrc.2015.05.041

M3 - Short survey

C2 - 26003731

AN - SCOPUS:84930924235

SN - 0006-291X

VL - 463

SP - 161

EP - 166

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

IS - 3

ER -

Proline-rich AKT substrate of 40-kDa (PRAS40) in the pathophysiology of cancer

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this